Cephalon Overview
- Founded
-
1987
- Status
-
Acquired/Merged
- Employees
-
800
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$6.8B
Cephalon General Information
Description
Cephalon was a provider and developer of medicines for central nervous system disorders, pain and cancer. The company's research, development, manufacturing, and marketing activities focused on therapies for central nervous system disorders, cancer, pain and inflammatory disease. It offered its products through distributors in the United States and internationally. The company was founded in 1987 and was headquartered in Frazer, Pennsylvania.
Contact Information
Primary Industry
Pharmaceuticals
Acquirer
Primary Office
- 41 Moores Road
- Frazer
- Malvern, PA 19355
- United States
Cephalon Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 14-Oct-2011 | $6.8B | 00.00 | Completed | Generating Revenue | |
| 3. Merger/Acquisition | 05-Apr-2011 | 00.00 | 00.00 | Cancelled | Generating Revenue | |
| 2. IPO | 25-Apr-1991 | Completed | Startup | |||
| 1. Early Stage VC | Completed | Startup |
Cephalon Patents
Cephalon Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220056125-A1 | Anti-par-2 antibodies and methods of use thereof | Pending | 18-Aug-2020 | 000000000 | 0 |
| AU-2017382850-A1 | Antibodies that specifically bind to human il-15 and uses thereof | Pending | 21-Dec-2016 | 00000000000 | |
| CA-3046387-A1 | Antibodies that specifically bind to human il-15 and uses thereof | Pending | 21-Dec-2016 | 00000000000 | |
| EP-3558369-A1 | Antibodies that specifically bind to human il-15 and uses thereof | Pending | 21-Dec-2016 | 00000000000 | |
| US-20220127352-A1 | Antibodies that specifically bind to human il-15 and uses thereof | Pending | 21-Dec-2016 | G01N33/6869 |
Cephalon Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Cephalon Former Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Ben Franklin Technology Partner of Southeastern Pennsylvania | Venture Capital | Minority | 000 0000 | 000000 0 | |
| New Leaf Venture | Venture Capital | Minority | 000 0000 | 000000 0 | |
| New Science Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Oak Investment Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
| SCALE Aviation | Venture Capital | Minority | 000 0000 | 000000 0 |
Cephalon Investments & Acquisitions (20)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000000 00 | 10-Jan-2012 | 0000000000 | Clinics/Outpatient Services | ||
| 00000 0 00000 | 01-Apr-2011 | 0000000000 | 00000 | Pharmaceuticals | |
| 000000000 000 | 29-Mar-2011 | 0000000000 | 00000 | Biotechnology | |
| 000000000 | 11-Feb-2011 | 0000 | 00000 | Biotechnology | |
| Alba Therapeutics (Larazotide Acetate Assets) | 09-Feb-2011 | Corporate Asset Purchase | 0000 | Buildings and Property | 00000 000 |
Cephalon Subsidiaries (2)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Fachklinik Osterhofen | Clinics/Outpatient Services | Osterhofen, Germany | 1999 |
| 00000 | Biotechnology | Basel, Switzerland | 0000 |
Cephalon Exits (1)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 0000 000000 | 05-Jan-2004 | 00000 00000 00 | 00.000 | Completed |
|